Health Trials

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

ConditionsHepatocellular Carcinoma Non-resectableCholangiocarcinoma Non-resectableLiver MetastasesLiver Malignant Tumors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTianjin Medical University Cancer Institute and Hospital

About this trial

This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.

Eligibility criteria

Qualifiers

Confirmed diagnosis of HCC by histology/ cytology or clinical criteria

Sign informed consent

When screening for age, the age should be ≥ 18 years old

Eligible for TACE treatment

Disqualifiers

Have any history of kidney disease or nephrotic syndrome

Evidence of extrahepatic spread (EHS)

Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control

Any condition representing a contraindication to TACE as determined by the investigators

Trial design

Treatments tested in this trial

  • TACE with ICI

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Tianjin Medical University Cancer Institute and Hospital

Lead sponsor

Source ClinicalTrials.gov